Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPYVLP01 CMV vaccine in healthy adults
NCT06145178Phase 1Completed
- Sponsor
- SpyBiotech
- Start
- Nov 2023
- Primary completion
- Jun 2025
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of SPYVLP01 in cytomegalovirus infection (CMV) (6 arms), sponsored by SpyBiotech. Primary endpoints: Safety profile of the vaccine with and without adjuvants at 12 months and Reactogenicity profile of the vaccine with and without adjuvants at 12 months. Started Nov 2023; status: completed.
02
Drugs
SPYVLP01
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT06145178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06145178.